Table 3 Clinical parameters, metabolic factors and adipose tissue compartment changes from baseline after 26 weeks of treatment in the per-protocol analysis
Characteristic | Mean ± SD change from baseline to 26 weeks | Mean [95% CI] changes from baseline (liraglutide vs placebo) | P value | |
|---|---|---|---|---|
Liraglutide (n = 20) | Placebo (n = 24) | |||
Clinical parameters | ||||
 Body weight (kg) | − 4.3 ± 3.4 | − 0.6 ± 2.2 | − 4.0 [− 5.8, − 2.3] | < 0.001 |
 BMI (kg/m2) | − 1.6 ± 1.4 | − 0.2 ± 0.9 | − 1.5 [− 2.2, − 0.8] | < 0.001 |
 Waist circumference (cm) | − 5 ± 4 | 0 ± 4 | − 5 [− 8, − 2] | 0.001 |
 Hip circumference (cm) | − 4 ± 5 | − 2 ± 3 | − 2 [− 5, 0] | 0.068 |
 Waist-hip ratio | − 0.01 ± 0.04 | 0.02 ± 0.05 | − 0.01 [− 0.04, 0.02] | 0.394 |
 Lean body mass (kg) | − 2.4 ± 2.4 | 0.4 ± 3.0 | − 2.8 [− 4.5, − 1.1] | 0.002 |
 Lean body mass (%) | 0.4 ± 1.6 | 0.8 ± 2.7 | − 0.4 [− 1.8, 1.0] | 0.605 |
Metabolic factors | ||||
 HbA1c (mmol/mol) | − 10.5 ± 9.1 | − 6.1 ± 8.8 | − 6.5 [− 11.5, − 1.5] | 0.011 |
 HbA1c (%) | − 1.0 ± 0.8 | − 0.6 ± 0.8 | − 0.6 [− 1.1, − 0.1] | 0.011 |
 Total cholesterol (mmol/L) | 0.06 ± 0.98 | − 0.37 ± 0.78 | 0.28 [− 0.26, 0.81] | 0.305 |
 HDL-cholesterol (mmol/L) | − 0.04 ± 0.12 | − 0.06 ± 0.11 | 0.02 [− 0.05, 0.10] | 0.510 |
 LDL-cholesterol (mmol/L) | 0.04 ± 0.66 | − 0.07 ± 0.68 | 0.08 [− 0.32, 0.48] | 0.689 |
 Triglycerides (mmol/L) | 0.12 ± 1.13 | − 0.38 ± 1.32 | 0.13 [− 0.47, 0.74] | 0.663 |
Adipose tissue compartments | ||||
 Subcutaneous AT (cm2) | − 26 ± 38 | − 11 ± 37 | − 15 [− 38, 7] | 0.182 |
 Visceral AT (cm2) | − 23 ± 27 | − 2 ± 17 | − 17 [− 32, − 3] | 0.020 |
 Epicardial AT (cm2) | 0 ± 2 | 1 ± 1 | − 1 [− 2, 0] | 0.139 |
 Paracardial AT (cm2) | − 1 ± 3 | 0 ± 3 | − 1 [− 3, 1] | 0.467 |
 Hepatic TGC (%) | − 1.9 ± 3.6 | − 3.2 ± 5.5 | − 0.3 [− 2.6, 2.0] | 0.807 |
 Myocardial TGC (%) | 0.1 ± 0.5 | − 0.1 ± 0.6 | 0.2 [− 0.1, 0.5] | 0.157 |